Botulinum neurotoxin 3D structures
From Proteopedia
(Difference between revisions)
| Line 12: | Line 12: | ||
*Type A Light Chain residues 1-425 | *Type A Light Chain residues 1-425 | ||
| - | **[[2g7k]], [[2g7p]], [[2g7q]], [[2imc]], [[3bwi]], [[3bon]], [[3qix]], [[2ise]], [[2isg]], [[2ish]], [[4ej5]] - CbCBN LC + Zn<br /> | + | **[[2g7k]], [[2g7p]], [[2g7q]], [[2imc]], [[3bwi]], [[3bon]], [[3qix]], [[2ise]], [[2isg]], [[2ish]], [[4ej5]], [[7ky2]], [[7kyf]], [[7kyh]] - CbCBN LC + Zn<br /> |
**[[5vgv]] - CbCBN LC + Cu<br /> | **[[5vgv]] - CbCBN LC + Cu<br /> | ||
**[[5vgx]] - CbCBN LC + Hg<br /> | **[[5vgx]] - CbCBN LC + Hg<br /> | ||
| Line 21: | Line 21: | ||
**[[3dda]], [[3ddb]] - CbCBN LC + synaptosomal-associated protein 25 peptide + Zn<br /> | **[[3dda]], [[3ddb]] - CbCBN LC + synaptosomal-associated protein 25 peptide + Zn<br /> | ||
**[[3zur]], [[3zus]] - CbCBN LC/synaptosomal-associated protein 25 translocation domain<br /> | **[[3zur]], [[3zus]] - CbCBN LC/synaptosomal-associated protein 25 translocation domain<br /> | ||
| - | **[[2g7n]], [[2ilp]], [[2imb]], [[3qiy]], [[3qiz]], [[3qj0]], [[4hev]], [[2ima]], [[5v8r]] – CbCBN LC + inhibitor + Zn<br /> | + | **[[2g7n]], [[2ilp]], [[2imb]], [[3qiy]], [[3qiz]], [[3qj0]], [[4hev]], [[2ima]], [[5v8r]], [[6xcb]], [[6xcc]], [[6xce]], [[6xcf]] – CbCBN LC + inhibitor + Zn<br /> |
**[[3c88]], [[3c89]], [[3c8a]], [[3c8b]], [[3boo]], [[3qw5]], [[3qw6]], [[3qw7]], [[3qw8]], [[3nf3]] – CbCBN LC + inhibitor peptide + Zn<br /> | **[[3c88]], [[3c89]], [[3c8a]], [[3c8b]], [[3boo]], [[3qw5]], [[3qw6]], [[3qw7]], [[3qw8]], [[3nf3]] – CbCBN LC + inhibitor peptide + Zn<br /> | ||
**[[4ks6]], [[4ktx]], [[5v8p]], [[5v8u]] - CbCBN LC (mutant) + inhibitor peptide + Zn<br /> | **[[4ks6]], [[4ktx]], [[5v8p]], [[5v8u]] - CbCBN LC (mutant) + inhibitor peptide + Zn<br /> | ||
| Line 32: | Line 32: | ||
**[[6mhj]] - CbCBN (mutant) <br /> | **[[6mhj]] - CbCBN (mutant) <br /> | ||
| - | *Type A receptor-binding domain residues 871-1296 | + | *Type A receptor-binding or heavy chain domain residues 871-1296 |
| - | **[[2vua]], [[3fuo]], [[5tpb]], [[5tpc]], [[5lr0]], [[5mk6]], [[5mk7]] – CbPBN <br /> | + | **[[2vua]], [[3fuo]], [[5tpb]], [[5tpc]], [[5lr0]], [[5mk6]], [[5mk7]], [[6f0o]], [[6f0p]], [[6twp]], [[6two]], [7dvl]] – CbPBN <br /> |
**[[4iqp]] – CbPBN (mutant)<br /> | **[[4iqp]] – CbPBN (mutant)<br /> | ||
**[[2vu9]] – CbPBN + polysaccharide + Mg<br /> | **[[2vu9]] – CbPBN + polysaccharide + Mg<br /> | ||
| Line 67: | Line 67: | ||
*Type B receptor-binding domain residues 857-1291 | *Type B receptor-binding domain residues 857-1291 | ||
| - | **[[1z0h]] – CbCBN <br /> | + | **[[1z0h]], [[6zvm]] – CbCBN <br /> |
| - | **[[6g5k]] - CbCBN + synaptotagmin-1 peptide<br /> | + | **[[6g5k]], [[6zvn]] - CbCBN + synaptotagmin-1 peptide<br /> |
**[[6qns]] - CbCBN (mutant) + synaptotagmin-1 peptide<br /> | **[[6qns]] - CbCBN (mutant) + synaptotagmin-1 peptide<br /> | ||
**[[2nm1]], [[4kbb]] - CbCBN + synaptotagmin-2 peptide<br /> | **[[2nm1]], [[4kbb]] - CbCBN + synaptotagmin-2 peptide<br /> | ||
| Line 106: | Line 106: | ||
**[[3ffz]], [[4zkt]] – CbCBN + Zn<br /> | **[[3ffz]], [[4zkt]] – CbCBN + Zn<br /> | ||
| + | **[[7k7y]], [[7k84]] - CbCBN + VHH<br /> | ||
*Type E Light Chain | *Type E Light Chain | ||
| Line 128: | Line 129: | ||
**[[2vxr]], [[3mpp]] - CbCBN <br /> | **[[2vxr]], [[3mpp]] - CbCBN <br /> | ||
| + | |||
| + | *Type H Light Chain | ||
| + | |||
| + | **[[6bvd]] - CbCBN LC + Zn<br /> | ||
*Type X Light Chain | *Type X Light Chain | ||
| Line 133: | Line 138: | ||
**[[6f4e]] - CbCBN LC<br /> | **[[6f4e]] - CbCBN LC<br /> | ||
**[[6f47]], [[6g8u]], [[6g8v]] - CbCBN LC + Zn<br /> | **[[6f47]], [[6g8u]], [[6g8v]] - CbCBN LC + Zn<br /> | ||
| + | **[[7kz7]] - CbCBN LC (mutant) + Zn<br /> | ||
}} | }} | ||
[[Category: Topic Page]] | [[Category: Topic Page]] | ||
Revision as of 08:32, 13 May 2021
3D structures of botulinum neurotoxin
Updated on 13-May-2021
